CN110075280A - 一种层粘连蛋白肽复合口服剂及其制备方法 - Google Patents
一种层粘连蛋白肽复合口服剂及其制备方法 Download PDFInfo
- Publication number
- CN110075280A CN110075280A CN201910321280.9A CN201910321280A CN110075280A CN 110075280 A CN110075280 A CN 110075280A CN 201910321280 A CN201910321280 A CN 201910321280A CN 110075280 A CN110075280 A CN 110075280A
- Authority
- CN
- China
- Prior art keywords
- extracting solution
- laminin
- parts
- oral agents
- auxiliary material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- YIYCUMYWGOOSNU-FMZZOXHWSA-N 2-[[(2s)-1-[(2s,3s)-2-[[(2s,3r)-2-[[2-[[(2s)-2-amino-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]acetic acid Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O YIYCUMYWGOOSNU-FMZZOXHWSA-N 0.000 title claims abstract description 22
- 150000001875 compounds Chemical class 0.000 title claims abstract description 21
- 239000000463 material Substances 0.000 claims abstract description 30
- 102000007547 Laminin Human genes 0.000 claims abstract description 29
- 108010085895 Laminin Proteins 0.000 claims abstract description 29
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 23
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 22
- 102000019197 Superoxide Dismutase Human genes 0.000 claims abstract description 21
- 108010012715 Superoxide dismutase Proteins 0.000 claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 230000003816 axenic effect Effects 0.000 claims abstract description 10
- 238000000746 purification Methods 0.000 claims abstract description 10
- 230000036039 immunity Effects 0.000 claims abstract description 8
- 239000004615 ingredient Substances 0.000 claims abstract description 7
- 230000003712 anti-aging effect Effects 0.000 claims abstract description 6
- 210000000936 intestine Anatomy 0.000 claims abstract description 5
- 239000006210 lotion Substances 0.000 claims abstract description 5
- 230000003860 sleep quality Effects 0.000 claims abstract description 5
- 210000002784 stomach Anatomy 0.000 claims abstract description 5
- 239000000047 product Substances 0.000 claims description 14
- 241000096284 Gynochthodes officinalis Species 0.000 claims description 11
- 240000002853 Nelumbo nucifera Species 0.000 claims description 11
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims description 11
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims description 11
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 11
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 claims description 10
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 claims description 10
- 241000169546 Lycium ruthenicum Species 0.000 claims description 10
- 240000004922 Vigna radiata Species 0.000 claims description 10
- 235000010721 Vigna radiata var radiata Nutrition 0.000 claims description 10
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 10
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 230000008901 benefit Effects 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 239000012982 microporous membrane Substances 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 241000196324 Embryophyta Species 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 240000007890 Leonurus cardiaca Species 0.000 claims description 2
- 238000000855 fermentation Methods 0.000 claims description 2
- 230000004151 fermentation Effects 0.000 claims description 2
- 230000000813 microbial effect Effects 0.000 claims description 2
- 230000008439 repair process Effects 0.000 abstract description 5
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 19
- 230000000694 effects Effects 0.000 description 10
- 241000207925 Leonurus Species 0.000 description 8
- -1 oxygen radical Chemical class 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102100027186 Extracellular superoxide dismutase [Cu-Zn] Human genes 0.000 description 2
- 101000836222 Homo sapiens Extracellular superoxide dismutase [Cu-Zn] Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000033065 inborn errors of immunity Diseases 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 244000013123 dwarf bean Species 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000021331 green beans Nutrition 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 210000000208 hepatic perisinusoidal cell Anatomy 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 150000002927 oxygen compounds Chemical class 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/533—Leonurus (motherwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/746—Morinda
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/446—Superoxide dismutase (1.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
- C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
- C12Y115/01001—Superoxide dismutase (1.15.1.1)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
本发明提供一种层粘连蛋白肽复合口服剂及其制备方法,所述的口服剂是以层粘连蛋白(LN)为主要成分,加有小分子活性肽、超氧化物歧化酶(SOD)以及无菌纯化水和辅料组成,其具体成分重量份配比为:层粘连蛋白0.1‑5份、小分子活性肽1‑6份、超氧化物歧化酶1‑6份、无菌纯化水1‑6份、辅料1‑3份。以层粘连蛋白为主要成分,既可加速受损细胞的修复,又可提高机体抵抗病菌的能力。本发明产品联合层粘连蛋白、小分子活性肽、超氧化物歧化酶发挥协同作用,极易吸收,具有良好的细胞修复、增强免疫力、提高睡眠质量、调理肠胃道、抗衰老、美容养颜等功能。
Description
技术领域
本发明是一种层粘连蛋白肽复合口服剂及其制备方法,可应用于药品、食品及保健品技术领域。
背景技术
免疫力是人体识别和消灭外来侵入的病毒、细菌等异物;处理自身衰老、损伤、死亡、变性的细胞以及识别和处理体内突变细胞和病毒感染细胞的能力,简而言之,免疫力就是人体对各种疾病的抵抗力。
现在随着社会的发展,我们的生活节奏越来越快,压力也越来越大,饮食及生活作息不规律等诸多因素是导致大多数人免疫力低下的主要原因。免疫力低下最直接的表现就是体质虚弱、营养不良、疲乏无力、食欲下降、面容憔悴精神不佳、睡眠障碍等一系列问题,且恢复期长易反复发作,长此以往会严重影响身心健康,还易诱发重大疾病。免疫系统跟人的健康息息相关,所以调节或增强免疫功能已成为预防和治疗疾病、维护健康的有效途径。
目前市场口服剂的种类繁多,良莠不齐,多为化学成分,吸收及效果不佳,有些长期服用或对人体造成副作用或致使免疫系统功能紊乱。随着科技及生物技术的发展,人们逐渐认识到生物制品存在的天然优势,生物组织的活性成分在医药、食品及保健品领域也越来越展现出卓越的品质和巨大的市场需求。
层粘连蛋白(LN),也称“层黏蛋白”“板层素”,它是构成细胞间质的一种非胶原糖蛋白,在肝内主要由内皮细胞及贮脂细胞合成,与胶原一起构成基底膜的成分,是胚胎发育中出现最早的细胞外基质成分,也是细胞外基质中最重要成分之一,LN对于机体细胞的再生修复有着不替代的作用。LN可与胶原、肝素、多糖、纤维、细胞及各种小分子活性肽等结合,为细胞提供营养和信息通道,构建良好的细胞生存环境;LN介导巨噬细胞与吞噬细胞的结合,发挥并加强细胞吞噬作用;LN所具有的独特的RGD序列,可结合11种整合素,起到细胞信号识别和传导的作用;同时LN具有细胞调控因子的作用,广泛参与并调控细胞的增殖、生长、分化、极化、粘黏、铺展、迁移、胚胎的发育及基因的表达等机体生命活动,是人体组织再生修复必需的高活性蛋白。研究证明,当机体处于非健康状态时,体内LN含量下降,细胞功能受损或丧失而无法发挥正常的免疫防御能力,此时向机体及时补充LN是保障机体健康和促进因免疫防御机制故障引起的机体疾病康复的必要途径。
目前LN多应用于烧创伤修复等方面,至今未见有以层粘连蛋白作为有效成分的应用于免疫调节或增强的相关产品上市。
发明内容
针对现有技术存在的不足,本发明目的是提供一种层粘连蛋白肽复合口服剂及其制备方法,以解决上述背景技术中提出的问题。
为了实现上述目的,本发明是通过如下的技术方案来实现:一种层粘连蛋白肽复合口服剂及其制备方法,所述的口服剂是以层粘连蛋白(LN)为主要成分,加有小分子活性肽、超氧化物歧化酶(SOD)以及无菌纯化水和辅料组成。
其具体成分重量份配比为:层粘连蛋白0.1-5份、小分子活性肽1-6份、超氧化物歧化酶1-6份、无菌纯化水1-6份、辅料1-3份。
其中辅料成分重量份配比为:以辅料为100%计包含以下重量百分比原料,巴戟天提取液10%-20%、益母草提取液10%-40%、莲子提取液10%-30%、绿豆提取液10%-30%、黑枸杞提取液10%-30%、黑糖提取液1%-5%、透明质酸钠0.1%-5%;
进一步地,所述的一种层粘连蛋白肽复合口服剂及其制备方法的制备方法,包括以下步骤:
(1)准确的选取所需配方量;
(2)将无菌纯化水及辅料中巴戟天提取液、益母草提取液、莲子提取液、绿豆提取液、黑枸杞提取液、黑糖提取液一起混合溶散,经离心或0.45μm微孔滤膜过滤,即得第一混合滤液;
(3)将步骤(2)中得到的第一混合滤液加热至80-90℃,待冷却至20-30℃时,加入层粘连蛋白、小分子活性肽、超氧化物歧化酶和辅料中的透明质酸钠搅拌均匀得第二混合液;
(4)将步骤(3)中得到的第二混合液经0.22μm滤膜除菌,按规格要求灌封于无菌瓶内,即为层粘连蛋白肽复合口服剂产品。
进一步地,所述的一种层粘连蛋白肽复合口服剂及其制备方法的用途,用于制备增强免疫力、提高睡眠质量、调理肠胃道、抗衰老、美容养颜的组合物。
进一步地,所述层粘连蛋白、小分子活性肽、超氧化物歧化酶可为动植物来源、微生物发酵。
所述的小分子活性肽对于细胞的作用是双重的,既可以补充营养需求修复缺损,又可以改善功能状态。同时具备承载工具和材料的双重职责。小分子活性肽能够通过细胞膜的渗透以原形直接进入细胞内,不需要再次消化,也不需要耗费能量。因此小分子活性肽的吸收、转化和利用,都是高效、完全、彻底的。小分子活性肽吸收的快速和主动性,对于因消化系统缺陷、障碍、损伤而不能吸收营养者,具有重要意义,另外小分子活性肽可以将吸附在本体上的营养物质运输到人体各细胞及组织处,连同小分子活性肽一起被人体吸收利用,从而调节免疫平衡。
所述的超氧化物歧化酶是一种源于生命体的活性物质,能消除生物体在新陈代谢过程中产生的有害物质。对人体不断地补充超氧化物歧化酶具有抗衰老的特殊效果。超氧化物歧化酶被视为生命科技中最具神奇魔力的酶、人体内的垃圾清道夫。超氧化物歧化酶是氧自由基的自然天敌,是机体内氧自由基的头号杀手,是生命健康之本。超氧化物歧化酶在生物体内的水平高低意味着衰老与死亡的直观指标;现已证实,由氧自由基引发的疾病多达60多种。它可对抗与阻断因氧自由基对细胞造成的损害,并及时修复受损细胞,复原因自由基造成的对细胞伤害。由于现代生活压力,环境污染,各种辐射和超量运动都会造成氧自由基大量形成;因此,生物抗氧化机制中超氧化物歧化酶的地位越来越重要。
所述的辅料中黑枸杞提取液可防止过早衰老、增强血管弹性、抑制过敏及炎症,现代科学也有大量研究证实,它能够滋补肝肾、益精明目和养血、增强免疫力;此外,黑枸杞能够保肝、降血糖、软化血管、降低血液中的胆固醇、甘油三酯水平,对脂肪肝和糖尿病患者具有一定的疗效。莲子提取液不仅有养心安神的作用,还能淡化黑色素,对于雀斑和脸色发黑都有很好的去除效果。黑糖提取液有加速细胞代谢、为细胞提供营养、淡化黑色素、美白净化皮肤的作用。绿豆提取液有抗菌、解毒、增白、淡化斑点、抑制青春痘的功效。巴戟天提取液有防止月经不调,小腹冷痛的功效。益母草制剂有利尿消肿、活血调经、兴奋人体子宫的作用。通过与透明质酸钠等其他营养成分配合使用,可以起到促进营养吸收的更理想效果。
本发明有益效果:本发明提供了一种层粘连蛋白肽复合口服剂及其制备方法,本发明产品的功能为:
1、本发明产品以层粘连蛋白为主要成分,既可加速受损细胞的修复,又可提高机体抵抗病菌的能力。
2、本发明产品联合层粘连蛋白、小分子活性肽、超氧化物歧化酶发挥协同作用,极易吸收,具有良好细胞修复、增强免疫力、提高睡眠质量、调理肠胃道、抗衰老、美容养颜等功能。
3、本发明产品为天然制剂,对人体无毒无害,是绿色环保产品,可用作日常保健食品,也可作为疾病预防及治疗用药。制备工艺简单,适合大规模生产。
具体实施方式
为使本发明实现的技术手段、创作特征、达成目的与功效易于明白了解,下面结合具体实施方式,进一步阐述本发明。
实施例1:
一种层粘连蛋白肽复合口服剂及其制备方法的制备方法,包括以下步骤:
(1)选取辅料:以辅料为100%计包含以下重量百分比原料,巴戟天提取液10%、益母草提取液20%、莲子提取液20%、绿豆提取液20%、黑枸杞提取液28%、黑糖提取液1%、透明质酸钠1%;
(2)将无菌纯化水2份与辅料0.5份中的巴戟天提取液,益母草提取液,莲子提取液,绿豆提取液,黑枸杞提取液、黑糖提取液一起混合溶散,经离心或0.45μm微孔滤膜过滤,即得第一混合滤液;
(3)将步骤(2)中所得的第一混合滤液加热至80℃,待冷却至25℃时,加入层粘连蛋白1.5份、小分子活性肽3份、超氧化物歧化酶3份和辅料中的透明质酸钠搅拌均匀得第二混合液;
(4)将步骤(3)中所得的第二混合液经0.22μm滤膜除菌,按规格要求灌封于无菌瓶内,所得即为层粘连蛋白肽复合口服剂产品。
实施例2:
一种层粘连蛋白肽复合口服剂及其制备方法的制备方法,包括以下步骤:
(1)选取辅料:以辅料为100%计包含以下重量百分比原料,巴戟天提取液15%、益母草提取液15%、莲子提取液25%、绿豆提取液25%、黑枸杞提取液15%、黑糖提取液1%、透明质酸钠4%;
(2)将纯水1.5份与辅料2.5份中的巴戟天提取液,益母草提取液,莲子提取液,绿豆提取液,黑枸杞提取液、黑糖提取液一起混合溶散,经离心或0.45μm微孔滤膜过滤,即得第一混合滤液;
(3)将步骤(2)中所得的第一混合滤液加热至80℃,待冷却至25℃时,加入层粘连蛋白0.5份、小分子活性肽2.5份、超氧化物歧化酶3份和辅料中的透明质酸钠搅拌均匀得第二混合液;
(4)将步骤(3)中所得的第二混合液经0.22μm滤膜除菌,按规格要求灌封于无菌瓶内,所得即为层粘连蛋白肽复合口服剂产品。
实施例3:
一种层粘连蛋白肽复合口服剂及其制备方法的制备方法,包括以下步骤:
(1)选取辅料:以辅料为100%计包含以下重量百分比原料,巴戟天提取液20%、益母草提取液30%、莲子提取液15%、绿豆提取液15%、黑枸杞提取液15%、黑糖提取液5%、透明质酸钠5%;
(2)将无菌纯化水2份、辅料1份中的巴戟天提取液,益母草提取液,莲子提取液,绿豆提取液,黑枸杞提取液、黑糖提取液一起混合溶散,经离心或0.45μm微孔滤膜过滤,即得第一混合滤液;
(3)将步骤(2)中所得的第一混合滤液加热至90℃,待冷却至20℃时,加入层粘连蛋白2份、小分子活性肽3份、超氧化物歧化酶2份和辅料中的透明质酸钠搅拌得第二混合液;
(4)将步骤(3)中所得的第二混合液经0.22μm滤膜除菌,按规格要求灌封于无菌瓶内,即为层粘连蛋白肽复合口服剂产品。
一种层粘连蛋白肽复合口服剂及其制备方法的用途,用于制备增强免疫力、提高睡眠质量、调理肠胃道、抗衰老、美容养颜的组合物,本组合物除可制成上述水剂,也可利用相关技术手段制成片剂、软胶囊、胶囊、粉剂、咀嚼片等剂型,层粘连蛋白、小分子活性肽、超氧化物歧化酶可为动植物来源、微生物发酵。
以上显示和描述了本发明的基本原理和主要特征和本发明的优点,对于本领域技术人员而言,显然本发明不限于上述示范性实施例的细节,而且在不背离本发明的精神或基本特征的情况下,能够以其他的具体形式实现本发明。因此,无论从哪一点来看,均应将实施例看作是示范性的,而且是非限制性的,本发明的范围由所附权利要求而不是上述说明限定,因此旨在将落在权利要求的等同要件的含义和范围内的所有变化囊括在本发明内。
此外,应当理解,虽然本说明书按照实施方式加以描述,但并非每个实施方式仅包含一个独立的技术方案,说明书的这种叙述方式仅仅是为清楚起见,本领域技术人员应当将说明书作为一个整体,各实施例中的技术方案也可以经适当组合,形成本领域技术人员可以理解的其他实施方式。
Claims (4)
1.一种层粘连蛋白肽复合口服剂及其制备方法,其特征在于:所述的口服剂是以层粘连蛋白(LN)为主要成分,加有小分子活性肽、超氧化物歧化酶(SOD)以及无菌纯化水和辅料组成,其具体成分重量份配比为:层粘连蛋白0.1-5份、小分子活性肽1-6份、超氧化物歧化酶1-6份、无菌纯化水1-6份、辅料1-3份。
2.根据权利要求1所述的一种层粘连蛋白肽复合口服剂及其制备方法,其特征在于制备方法包括以下步骤:
(1)选取辅料:以辅料为100%计包含以下重量百分比原料,巴戟天提取液10%-20%、益母草提取液10%-40%、莲子提取液10%-30%、绿豆提取液10%-30%、黑枸杞提取液10%-30%、黑糖提取液1%-5%、透明质酸钠0.1%-5%;
(2)将无菌纯化水及辅料中巴戟天提取液、益母草提取液、莲子提取液、绿豆提取液、黑枸杞提取液、黑糖提取液一起混合溶散,经离心或0.45μm微孔滤膜过滤,即得第一混合滤液;
(3)将步骤(2)中得到的第一混合滤液加热至80-90℃,待冷却至20-30℃时,加入层粘连蛋白、小分子活性肽、超氧化物歧化酶和辅料中的透明质酸钠搅拌均匀得第二混合液;
(4)将步骤(3)中得到的第二混合液经0.22μm滤膜除菌,按规格要求灌封于无菌瓶内,即为层粘连蛋白肽复合口服剂产品。
3.根据权利要求1至2任一所述的一种层粘连蛋白肽复合口服剂及其制备方法的用途,用于制备增强免疫力、提高睡眠质量、调理肠胃道、抗衰老、美容养颜的组合物。
4.根据权利要求1所述的一种层粘连蛋白肽复合口服剂及其制备方法,其特征在于:所述层粘连蛋白、小分子活性肽、超氧化物歧化酶可为动植物来源、微生物发酵。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910321280.9A CN110075280A (zh) | 2019-04-30 | 2019-04-30 | 一种层粘连蛋白肽复合口服剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910321280.9A CN110075280A (zh) | 2019-04-30 | 2019-04-30 | 一种层粘连蛋白肽复合口服剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110075280A true CN110075280A (zh) | 2019-08-02 |
Family
ID=67415838
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910321280.9A Pending CN110075280A (zh) | 2019-04-30 | 2019-04-30 | 一种层粘连蛋白肽复合口服剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110075280A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110664651A (zh) * | 2019-11-16 | 2020-01-10 | 许帅辉 | 一种治疗口腔粘膜修护的组合物及其制备方法 |
CN110755281A (zh) * | 2019-11-16 | 2020-02-07 | 许帅辉 | 一种皮肤修复及护理组合物及其制备方法 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1089852A (zh) * | 1993-01-21 | 1994-07-27 | 陈玉春 | 含有生物活性因子核苷酸多肽类的天然生物口服液 |
CN1285193A (zh) * | 1999-08-18 | 2001-02-28 | 凌沛学 | 透明质酸口服美肤保健品的制备和应用 |
CN1320607A (zh) * | 2000-04-27 | 2001-11-07 | 上海博德基因开发有限公司 | 一种新的多肽——层粘连蛋白19和编码这种多肽的多核苷酸 |
CN101873854A (zh) * | 2007-10-09 | 2010-10-27 | 内华达高等教育系统董事会,代表内华达大学雷诺校区 | 层粘连蛋白、衍生物和包含它们的组合物以及它们的治疗性应用方法 |
CN101986881A (zh) * | 2009-07-31 | 2011-03-23 | 桐乡市恒基生物科技有限公司 | 一种透明质酸口服液及其制备方法 |
CN103191070A (zh) * | 2013-03-29 | 2013-07-10 | 湖南大学 | 一种超氧化物歧化酶口服含片及制备方法 |
CN103298935A (zh) * | 2007-08-15 | 2013-09-11 | 阿穆尼克斯公司 | 用于改善生物活性多肽性能的组合物和方法 |
CN108741101A (zh) * | 2018-05-25 | 2018-11-06 | 渤海大学 | 一种女士型海参肽口服液 |
CN108835630A (zh) * | 2018-08-02 | 2018-11-20 | 中国农业大学 | 一种具有高sod酶活力的口服液及其制备方法 |
-
2019
- 2019-04-30 CN CN201910321280.9A patent/CN110075280A/zh active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1089852A (zh) * | 1993-01-21 | 1994-07-27 | 陈玉春 | 含有生物活性因子核苷酸多肽类的天然生物口服液 |
CN1285193A (zh) * | 1999-08-18 | 2001-02-28 | 凌沛学 | 透明质酸口服美肤保健品的制备和应用 |
CN1320607A (zh) * | 2000-04-27 | 2001-11-07 | 上海博德基因开发有限公司 | 一种新的多肽——层粘连蛋白19和编码这种多肽的多核苷酸 |
CN103298935A (zh) * | 2007-08-15 | 2013-09-11 | 阿穆尼克斯公司 | 用于改善生物活性多肽性能的组合物和方法 |
CN101873854A (zh) * | 2007-10-09 | 2010-10-27 | 内华达高等教育系统董事会,代表内华达大学雷诺校区 | 层粘连蛋白、衍生物和包含它们的组合物以及它们的治疗性应用方法 |
CN101986881A (zh) * | 2009-07-31 | 2011-03-23 | 桐乡市恒基生物科技有限公司 | 一种透明质酸口服液及其制备方法 |
CN103191070A (zh) * | 2013-03-29 | 2013-07-10 | 湖南大学 | 一种超氧化物歧化酶口服含片及制备方法 |
CN108741101A (zh) * | 2018-05-25 | 2018-11-06 | 渤海大学 | 一种女士型海参肽口服液 |
CN108835630A (zh) * | 2018-08-02 | 2018-11-20 | 中国农业大学 | 一种具有高sod酶活力的口服液及其制备方法 |
Non-Patent Citations (5)
Title |
---|
国家药典委员会 编: "《中华人民共和国药典 临床用药须知 中药饮片卷 2015年版》", 30 September 2017, 中国医药科技出版社 * |
川流不息123: "小分子蛋白肽:人类健康的新型免疫剂", 《网址:HTTPS://WWW.JIANSHU.COM/P/91DAF648933D》 * |
白鸿,等: "《保健食品功效成分检测方法》", 31 May 2011 * |
邱保国,等: "《简明中药临床实用手册》", 31 January 2012, 中原农民出版社 * |
陈士林,等: "《中华医学百科全书 中药资源学》", 30 April 2018, 中国协和医科大学出版社 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110664651A (zh) * | 2019-11-16 | 2020-01-10 | 许帅辉 | 一种治疗口腔粘膜修护的组合物及其制备方法 |
CN110755281A (zh) * | 2019-11-16 | 2020-02-07 | 许帅辉 | 一种皮肤修复及护理组合物及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109123643A (zh) | 一种谷物代餐球的制备方法 | |
CN103976203B (zh) | 一种美容养颜的果冻及其制备方法 | |
CN1814167A (zh) | 一种用于糖尿病的保健品 | |
CN106579389A (zh) | 一种通便、减肥、美容、增强免疫力的组合物 | |
CN105567771A (zh) | 一种猪皮小肽螯合物及其制备方法和应用 | |
CN101828714B (zh) | 一种用于延缓衰老的保健食品 | |
CN103263012A (zh) | 一种药食同源的保健食品及其制备方法 | |
CN110075280A (zh) | 一种层粘连蛋白肽复合口服剂及其制备方法 | |
WO2018188525A1 (zh) | 一种改善机体内循环,延缓衰老的组合物及其用途 | |
CN107156416A (zh) | 一种护肤养颜黑枸杞糖果及其制备方法 | |
CN105541967A (zh) | 一种具有抗凝活血作用的水蛭小肽螯合物及其制备方法 | |
KR101127419B1 (ko) | 백토, 초유 및 발효한방활성액을 포함하는 화장료 조성물 및 그 제조방법 | |
KR20080090808A (ko) | 피부미용을 위한 건강보조식품의 조성물 | |
CN100479671C (zh) | 一种复方微米松花魔芋露减肥降糖酸奶制备方法 | |
CN100506085C (zh) | 一种能够提高产妇免疫力的红糖保健品 | |
CN114041603A (zh) | 肽-锌螯合物在抗过敏产品中的应用 | |
CN114432384A (zh) | 一种低氘水龙脑雾化护眼液 | |
CN113826908A (zh) | 一种具有增强体质和抗衰老功效的功能产品及其制备方法 | |
CN107549614A (zh) | 一种食疗调理三高的膳食粉及其制备方法 | |
CN106176510A (zh) | 一种用于美容保健的口服物及相应的美容保健组合物 | |
CN108660174B (zh) | 一种抗疲劳、促进肠道益生菌增殖的芝麻生物活性肽 | |
CN102948733B (zh) | 一种特殊食用生命营养液的生产方法和配方 | |
CN105995971A (zh) | 一种促进糖尿病康复的营养流食及其制备方法 | |
CN101797280B (zh) | 一种防衰老的中药制剂 | |
CN100534521C (zh) | 抗疲劳、调节和增强机体免疫功能的保健酒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20220411 Address after: 471000 group 13, Yuquan village, Liuquan Town, Yiyang County, Luoyang City, Henan Province Applicant after: Xu Yihui Address before: 471600 Han Cheng Zhen Qin Wang Cun, Yiyang County, Luoyang City, Henan Province Applicant before: Wang Congfei |
|
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190802 |